• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

B + L, TPV join forces

Article

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV) plan to globally distribute a femtosecond laser capable of performing both cataract and refractive procedures on one platform.

Rochester, NY-Bausch + Lomb (B+L) and Technolas Perfect Vision GmbH (TPV) plan to distribute globally a femtosecond laser capable of performing both cataract and refractive procedures on one platform.

TPV was established in 2009 through a joint venture between B+L and 20/10 Perfect Vision AG to develop advanced refractive and cataract technologies. Under the terms of the agreement, TPV will develop and manufacture its laser system from its facilities in Munich, Germany, and will service the product through its current worldwide service organization. B+L Surgical will globally distribute the laser.

Financial terms were not disclosed. TPV will continue to commercialize its refractive portfolio.

“Femtosecond laser technology for cataract procedures promises to be one of the most significant clinical advances in cataract surgery in 40 years,” said Robert E. Grant, chief executive officer and president of B+L Surgical. “The TPV femtosecond laser platform, which uniquely supports refractive and cataract procedures, is a natural complement to our portfolio of cataract products. This is the first of many new technologies we are pursuing focused on enhancing a physician’s ability to improve patient outcomes.”

Commercialization is expected to begin in the second half of this year. TPV previously announced that it has filed for FDA 510(k) clearance for the laser.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.